[go: up one dir, main page]

NO20082643L - Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft - Google Patents

Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft

Info

Publication number
NO20082643L
NO20082643L NO20082643A NO20082643A NO20082643L NO 20082643 L NO20082643 L NO 20082643L NO 20082643 A NO20082643 A NO 20082643A NO 20082643 A NO20082643 A NO 20082643A NO 20082643 L NO20082643 L NO 20082643L
Authority
NO
Norway
Prior art keywords
preparation
cancer
isoquinolinaminopyrazole
derivatives
treatment
Prior art date
Application number
NO20082643A
Other languages
English (en)
Inventor
Li Chen
Guy Georges
Alfred Mertens
Xihan Wu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082643(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20082643L publication Critical patent/NO20082643L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Forbindelsene med formel I: (I) deres farmasøytisk akseptable salter, enantiomere former, diastereoisomerer og racemater, fremstilling av ovennevnte forbindelser, medikamenter inneholdende dem og fremstilling av dem, så vel som anvendelse av ovennevnte forbindelser ved begrensning eller forebygging av sykdommer så som kreft, er gjenstand for foreliggende oppfinnelse.
NO20082643A 2005-12-19 2008-06-05 Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft NO20082643L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05027720 2005-12-19
PCT/EP2006/012112 WO2007071348A1 (en) 2005-12-19 2006-12-15 Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer

Publications (1)

Publication Number Publication Date
NO20082643L true NO20082643L (no) 2008-09-01

Family

ID=36337671

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082643A NO20082643L (no) 2005-12-19 2008-06-05 Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft

Country Status (15)

Country Link
US (1) US7572809B2 (no)
EP (1) EP1966190A1 (no)
JP (1) JP2009519918A (no)
KR (1) KR20080076963A (no)
CN (1) CN101341145A (no)
AR (1) AR058362A1 (no)
AU (1) AU2006328997A1 (no)
BR (1) BRPI0620012A2 (no)
CA (1) CA2633101A1 (no)
IL (1) IL191984A0 (no)
NO (1) NO20082643L (no)
RU (1) RU2008129381A (no)
TW (1) TW200730502A (no)
WO (1) WO2007071348A1 (no)
ZA (1) ZA200805163B (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1846394E (pt) 2005-02-04 2012-01-05 Astrazeneca Ab Derivados de pirazolilaminopiridina úteis como inibidores da quinase
JP2008081492A (ja) * 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
WO2009010455A2 (en) * 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as modulators of metabotropic glutamate receptors
WO2009010871A2 (en) * 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as antagonists of adenosine a3 receptor
JP5209254B2 (ja) * 2007-08-30 2013-06-12 日本曹達株式会社 置換フェノキシアザビシクロオクタン誘導体の製造方法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX358640B (es) 2008-01-04 2018-08-29 Intellikine Llc Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas.
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
JP5789252B2 (ja) * 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
US8258149B2 (en) * 2009-05-08 2012-09-04 Hoffmann-La Roche Inc. Isoquinoline derivatives
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US20130296363A1 (en) * 2010-09-01 2013-11-07 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
EP2441755A1 (en) * 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
PH12013501489A1 (en) * 2010-12-17 2013-08-28 Hoffmann La Roche Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
TWI546305B (zh) 2011-01-10 2016-08-21 英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
JP6085866B2 (ja) 2011-02-28 2017-03-01 アレイ バイオファーマ、インコーポレイテッド セリン／トレオニンキナーゼインヒビター
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
BR112014002675A2 (pt) 2011-08-04 2017-02-21 Array Biopharma Inc "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
PL2820009T3 (pl) 2012-03-01 2018-09-28 Array Biopharma, Inc. Inhibitory kinaz serynowo/treoninowych
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CA2882750A1 (en) * 2012-08-27 2014-03-06 Jim Blake Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
CN105102000B (zh) 2012-11-01 2021-10-22 无限药品公司 使用pi3激酶亚型调节剂的癌症疗法
JO3377B1 (ar) * 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
EA201691872A1 (ru) 2014-03-19 2017-04-28 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
WO2015150995A1 (en) 2014-04-04 2015-10-08 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
CN103922965B (zh) * 2014-04-28 2016-08-24 西安瑞联新材料股份有限公司 一种4-甲氧基-2-甲基苯乙腈的合成方法
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PL3303348T3 (pl) * 2015-05-28 2020-02-28 Theravance Biopharma R&D Ip, Llc Związki naftyrydyny jako inhibitory kinazy JAK
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
US20180282282A1 (en) 2017-03-30 2018-10-04 Genentech, Inc. Isoquinolines as inhibitors of hpk1
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
JP2023502857A (ja) * 2019-10-25 2023-01-26 メルク・シャープ・アンド・ドーム・エルエルシー Ｌｒｒｋ２阻害薬としてのｎ－（ヘテロアリール）キナゾリン－２－アミン誘導体、医薬組成物及びその使用
CN111039940B (zh) * 2019-12-31 2022-10-21 北京鑫开元医药科技有限公司 一种Aurora A激酶抑制剂、制备方法、药物组合物及其用途
US20240246903A1 (en) * 2021-05-04 2024-07-25 Board Of Regents, The University Of Texas System Indanone and tetraloneketo or hydroxyl oximes as cancel therapeutics
FR3132098B1 (fr) 2022-01-25 2024-08-30 Rhodia Operations Procédé de préparation d’acide p-hydroxycinnamiques
CN114573506B (zh) * 2022-03-21 2022-09-30 邦恩泰(山东)生物医药科技集团股份有限公司 药物中间体及合成方法、异喹啉类衍生物及其合成方法
CN117126047A (zh) * 2023-08-15 2023-11-28 山西立业制药有限公司 一种桂美酸原料药的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
ATE309241T1 (de) * 1999-09-10 2005-11-15 Merck & Co Inc Tyrosin kinase inhibitoren
US20050209297A1 (en) 2000-08-31 2005-09-22 Pfizer Inc Pyrazole derivatives
CZ2003468A3 (cs) * 2000-08-31 2004-05-12 Pfizeráproductsáinc Deriváty pyrazolu a jejich použití jako inhibitorů proteinkinázy
AU2001296871A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
HUP0400639A3 (en) * 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
JP4523271B2 (ja) 2001-06-01 2010-08-11 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール化合物
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
ES2299080T3 (es) * 2004-05-14 2008-05-16 Millennium Pharmaceuticals, Inc. Compuestos y metodos para inhibir la progresion mitotica mediante la inhibicion de quinasas aurora.
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors

Also Published As

Publication number Publication date
US7572809B2 (en) 2009-08-11
AR058362A1 (es) 2008-01-30
BRPI0620012A2 (pt) 2011-10-25
ZA200805163B (en) 2009-06-24
WO2007071348A1 (en) 2007-06-28
IL191984A0 (en) 2008-12-29
TW200730502A (en) 2007-08-16
JP2009519918A (ja) 2009-05-21
EP1966190A1 (en) 2008-09-10
CA2633101A1 (en) 2007-06-28
KR20080076963A (ko) 2008-08-20
AU2006328997A1 (en) 2007-06-28
RU2008129381A (ru) 2010-01-27
US20070179151A1 (en) 2007-08-02
CN101341145A (zh) 2009-01-07

Similar Documents

Publication Publication Date Title
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
NO20084845L (no) 2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig
NO20090631L (no) Morpholin pyrimidin derivativer anvendelige i behandlingen av proliferative lidelser
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
NO20053775L (no) Diazepinoindol derivater som kinaseinhibitorer.
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20082730L (no) Morfolinopyrimidinderivater og deres anvendelse i terapi
NO20092737L (no) Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer
NO20061743L (no) Kinazolinderivater
SE0402735D0 (sv) Novel compounds
NO20075113L (no) Proteinkinaseinhibitorer
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
NO20081844L (no) Terapeutiske forbindelser
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20084496L (no) Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer
NO20073719L (no) Kjemiske forbindelser
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
NO20074703L (no) Antibakterielle piperidinderivater
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
NO20082445L (no) Neuropeptid-2 reseptor-agonister
NO20054842L (no) Kjemiske forbindelser
NO20082496L (no) Pyrazinderivater
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
NO20055891L (no) Kinazolinderivater som aurorakinaseinhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application